Setting A New 52 Week Low, FibroGen Inc (Nasdaq:FGEN) Closing At $37.97

0
4
Shipwreck freeimages.com/Roger Buser
Shipwreck freeimages.com/Roger Buser

FibroGen Inc (Nasdaq:FGEN)

December 7th, 2018

Amidst falling markets FibroGen Inc finished Friday’s trading session down 7.23%, a $2.96 decrease to close on $37.97. As well as the drop in value, FibroGen Inc hit a new 52 week low of $37.64, breaking the previous low of $37.85 from earlier this July. FibroGen Inc bounced 12.46% between low and high.

FGEN was outperformed by the rest of the Healthcare sector which went down just 2.51%.

Analysis results from 5 analysts suggest that FibroGen Inc could increase significantly (73%), while Finbox has calculated (with medium uncertainty) a fair value price of $53.00.

Market Sectors

The market sectors were mixed Friday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.40%), while Information Technology saw the biggest drop (3.53%). Healthcare has seen the biggest year-to-date gain at 9.38%. The biggest loss this year has been the Materials sector dropping 15%.

Utilities saw the biggest turnaround from its 5-day performance of 2.89%, as it went up 0.40%. Real Estate saw a turn around from its 5-day performance of 1.28% trading down 1.44%.

Sector Breakdown

  • Utilities went up with a 0.40% change.
  • Energy went down with a -0.64% change.
  • Consumer Staples went down with a -1.29% change.
  • Real Estate went down with a -1.44% change.
  • Financials went down with a -1.84% change.
  • Communication Services went down with a -2.09% change.
  • Healthcare went down with a -2.51% change.
  • Materials went down with a -2.54% change.
  • Industrials went down with a -2.62% change.
  • Consumer Discretionary went down with a -3.08% change.
  • Information Technology went down with a -3.53% change.

FibroGen Inc Info

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

All amounts in USD unless otherwise indicated

FGEN daily update
FGEN daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.